Search Results

You are looking at 1 - 10 of 65 items for :

  • tyrosine kinase inhibitors x
Clear All
Kirsten E. Stewart Department of Head and Neck Surgery, St John’s Hospital at Howden, Livingston, United Kingdom

Search for other papers by Kirsten E. Stewart in
Google Scholar
PubMed
Close
,
Mark W.J. Strachan Metabolic Unit, Western General Hospital, Edinburgh, United Kingdom

Search for other papers by Mark W.J. Strachan in
Google Scholar
PubMed
Close
,
Devraj Srinivasan Department of Oncology, Western General Hospital, Edinburgh, United Kingdom

Search for other papers by Devraj Srinivasan in
Google Scholar
PubMed
Close
,
Morna MacNeill Department of Pathology, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom

Search for other papers by Morna MacNeill in
Google Scholar
PubMed
Close
,
Lucy Wall Department of Oncology, Western General Hospital, Edinburgh, United Kingdom

Search for other papers by Lucy Wall in
Google Scholar
PubMed
Close
, and
Iain J. Nixon Department of Head and Neck Surgery, St John’s Hospital at Howden, Livingston, United Kingdom

Search for other papers by Iain J. Nixon in
Google Scholar
PubMed
Close

). What Does This Case Report Add? This case illustrates a patient with locally advanced DTC treated with tyrosine kinase inhibitor (TKI) therapy, which markedly reduced tumour volume and allowed subsequent successful surgical resection without

Free access
Satoshi Koyama Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine, Yonago, Japan

Search for other papers by Satoshi Koyama in
Google Scholar
PubMed
Close
,
Naritomo Miyake Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine, Yonago, Japan

Search for other papers by Naritomo Miyake in
Google Scholar
PubMed
Close
,
Kazunori Fujiwara Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine, Yonago, Japan

Search for other papers by Kazunori Fujiwara in
Google Scholar
PubMed
Close
,
Tsuyoshi Morisaki Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine, Yonago, Japan

Search for other papers by Tsuyoshi Morisaki in
Google Scholar
PubMed
Close
,
Takahiro Fukuhara Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine, Yonago, Japan

Search for other papers by Takahiro Fukuhara in
Google Scholar
PubMed
Close
,
Hiroya Kitano Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine, Yonago, Japan
Center for Head and Neck Surgery, Kusatsu General Hospital, Kusatsu, Japan

Search for other papers by Hiroya Kitano in
Google Scholar
PubMed
Close
, and
Hiromi Takeuchi Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine, Yonago, Japan

Search for other papers by Hiromi Takeuchi in
Google Scholar
PubMed
Close

strategies are required to improve the prognosis. Lenvatinib is an oral tyrosine kinase inhibitor targeting VEGFR1–3, FGFR1–4, RET, KIT, and PDGFRβ [ 6 - 8 ]. It was associated with a marked improvement in progression-free survival in patients with

Free access
Laura Ximena Kattah Martinez Pontificia Universidad Javeriana, Bogotá, Colombia

Search for other papers by Laura Ximena Kattah Martinez in
Google Scholar
PubMed
Close
,
Lisseth Fernanda Marín Carrillo Pontificia Universidad Javeriana, Bogotá, Colombia

Search for other papers by Lisseth Fernanda Marín Carrillo in
Google Scholar
PubMed
Close
, and
Leonardo Rojas Melo Pontificia Universidad Javeriana, Bogotá, Colombia

Search for other papers by Leonardo Rojas Melo in
Google Scholar
PubMed
Close

What Is Known About This Topic? Several side effects have been described with the use of tyrosine kinase inhibitors like sorafenib. Nonetheless, only 9 cases of pancreatitis related to sorafenib treatment have been described, all of them

Free access
Markus Eszlinger Departments of Oncology, Pathology and Laboratory Medicine, Biochemistry and Molecular Biology, and Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Heritage Medical Research Building, Calgary, Alberta, Canada
Institute of Pathology, University Hospital Halle (Saale), Halle (Saale), Germany

Search for other papers by Markus Eszlinger in
Google Scholar
PubMed
Close
,
Paul Stewardson Department of Medical Science and Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Paul Stewardson in
Google Scholar
PubMed
Close
,
John B McIntyre Precision Oncology Hub Laboratory, Alberta Health Services, Tom Baker Cancer Centre, Calgary, Alberta, Canada

Search for other papers by John B McIntyre in
Google Scholar
PubMed
Close
,
Adrian Box Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Adrian Box in
Google Scholar
PubMed
Close
,
Moosa Khalil Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Moosa Khalil in
Google Scholar
PubMed
Close
,
Martin Hyrcza Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Martin Hyrcza in
Google Scholar
PubMed
Close
,
Konstantin Koro Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Konstantin Koro in
Google Scholar
PubMed
Close
,
Dean Ruether Section of Medical Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Dean Ruether in
Google Scholar
PubMed
Close
,
Jiahui Wu Department of Medical Science and Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Jiahui Wu in
Google Scholar
PubMed
Close
, and
Ralf Paschke Departments of Medicine, Oncology, Pathology and Laboratory Medicine, Biochemistry and Molecular Biology, and Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Heritage Medical Research Building, Calgary, Alberta, Canada

Search for other papers by Ralf Paschke in
Google Scholar
PubMed
Close

Introduction The neurotrophic tyrosine kinase receptor (NTRK) inhibitors, larotrectinib and entrectinib, were approved by the United States Food & Drug Administration (FDA) for the treatment of NTRK fusion-positive solid tumors that are

Open access
Luisa Paschke Department of Endocrinology and Nephrology, Division of Endocrinology, University Clinic Leipzig, Leipzig, Germany
Department of Endocrinology and Nephrology, Division of Nephrology, University Clinic Leipzig, Leipzig, Germany

Search for other papers by Luisa Paschke in
Google Scholar
PubMed
Close
,
Thomas Lincke Department of Radiology, Division of Nuclear Medicine, University Clinic Leipzig, Leipzig, Germany

Search for other papers by Thomas Lincke in
Google Scholar
PubMed
Close
,
Katja Sibylle Mühlberg Department of Angiology, University Clinic Leipzig, Leipzig, Germany

Search for other papers by Katja Sibylle Mühlberg in
Google Scholar
PubMed
Close
,
Wolfram J. Jabs Department of Nephrology, Vivantes Clinics, Berlin, Germany

Search for other papers by Wolfram J. Jabs in
Google Scholar
PubMed
Close
,
Tom H. Lindner Department of Endocrinology and Nephrology, Division of Nephrology, University Clinic Leipzig, Leipzig, Germany

Search for other papers by Tom H. Lindner in
Google Scholar
PubMed
Close
, and
Ralf Paschke Division of Endocrinology, University of Calgary, Calgary, Alberta, Canada

Search for other papers by Ralf Paschke in
Google Scholar
PubMed
Close

treatment with lenvatinib and no concerning co-medications were reported. What Does This Case Report Add? We report two severe AEs of anti-VEGF tyrosine kinase inhibitor treatment which were not reported in the phase III trials. Our case

Free access
Francisco Sousa Santos Endocrinology Department, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal
Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Francisco Sousa Santos in
Google Scholar
PubMed
Close
,
Rita Joana Santos Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Rita Joana Santos in
Google Scholar
PubMed
Close
, and
Valeriano Leite Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Faculty of Medical Sciences of Lisbon, Lisbon, Portugal

Search for other papers by Valeriano Leite in
Google Scholar
PubMed
Close

a part in the pathogenesis of thyroid cancer and these represent potential treatment targets [ 6 ]. As such, several multitargeted tyrosine kinase inhibitors (TKIs) have been investigated for the treatment of RAI-refractory thyroid cancer with the

Free access
Simone De Leo Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy

Search for other papers by Simone De Leo in
Google Scholar
PubMed
Close
,
Carla Colombo Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy

Search for other papers by Carla Colombo in
Google Scholar
PubMed
Close
,
Marta Di Stefano Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy

Search for other papers by Marta Di Stefano in
Google Scholar
PubMed
Close
,
Antonella Dubini Division of Laboratory Medicine, IRCCS Istituto Auxologico Italiano, Milan, Italy

Search for other papers by Antonella Dubini in
Google Scholar
PubMed
Close
,
Silvia Cozzi Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy

Search for other papers by Silvia Cozzi in
Google Scholar
PubMed
Close
,
Luca Persani Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy
Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy

Search for other papers by Luca Persani in
Google Scholar
PubMed
Close
, and
Laura Fugazzola Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy

Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
Close

biological characteristics of this tumor, which has a relatively low growth rate and is poorly symptomatic. Nevertheless, patients experience a relevant weight decrease when treatment with a tyrosine kinase inhibitor (TKI) is started, such as lenvatinib

Free access
Sita Virakul Departments of Immunology, University Medical Center Rotterdam
Internal Medicine, Erasmus MC, University Medical Center Rotterdam

Search for other papers by Sita Virakul in
Google Scholar
PubMed
Close
,
Leendert van Steensel Departments of Immunology, University Medical Center Rotterdam

Search for other papers by Leendert van Steensel in
Google Scholar
PubMed
Close
,
Virgil A.S.H. Dalm Departments of Immunology, University Medical Center Rotterdam

Search for other papers by Virgil A.S.H. Dalm in
Google Scholar
PubMed
Close
,
Dion Paridaens Rotterdam Eye Hospital, Rotterdam, The Netherlands
Department of Ophthalmology, Geneva University Hospitals, Geneva, Switzerland

Search for other papers by Dion Paridaens in
Google Scholar
PubMed
Close
,
P. Martin van Hagen Departments of Immunology, University Medical Center Rotterdam
Internal Medicine, Erasmus MC, University Medical Center Rotterdam
Rotterdam Eye Hospital, Rotterdam, The Netherlands

Search for other papers by P. Martin van Hagen in
Google Scholar
PubMed
Close
, and
Willem A. Dik Departments of Immunology, University Medical Center Rotterdam

Search for other papers by Willem A. Dik in
Google Scholar
PubMed
Close

fibroblast functions In recent years numerous novel, targeted therapies have been introduced in clinical practice, like the biologicals and tyrosine kinase inhibitors (TKIs). Therapeutic strategies that target specific cytokines, growth factors or

Free access
Haruhiko Yamazaki Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama City, Kanagawa, Japan
Department of Surgery, Ito Hospital, Shibuya-ku, Tokyo, Japan

Search for other papers by Haruhiko Yamazaki in
Google Scholar
PubMed
Close
,
Kiminori Sugino Department of Surgery, Ito Hospital, Shibuya-ku, Tokyo, Japan

Search for other papers by Kiminori Sugino in
Google Scholar
PubMed
Close
,
Ryohei Katoh Department of Pathology, Ito Hospital, Shibuya-ku, Tokyo, Japan

Search for other papers by Ryohei Katoh in
Google Scholar
PubMed
Close
,
Kenichi Matsuzu Department of Surgery, Ito Hospital, Shibuya-ku, Tokyo, Japan

Search for other papers by Kenichi Matsuzu in
Google Scholar
PubMed
Close
,
Wataru Kitagawa Department of Surgery, Ito Hospital, Shibuya-ku, Tokyo, Japan

Search for other papers by Wataru Kitagawa in
Google Scholar
PubMed
Close
,
Mitsuji Nagahama Department of Surgery, Ito Hospital, Shibuya-ku, Tokyo, Japan

Search for other papers by Mitsuji Nagahama in
Google Scholar
PubMed
Close
,
Aya Saito Department of Surgery, Yokohama City University School of Medicine, Yokohama City, Kanagawa, Japan

Search for other papers by Aya Saito in
Google Scholar
PubMed
Close
, and
Koichi Ito Department of Surgery, Ito Hospital, Shibuya-ku, Tokyo, Japan

Search for other papers by Koichi Ito in
Google Scholar
PubMed
Close

RAI. However, some FTCs become refractory to RAI. Multi-tyrosine kinase inhibitors such as sorafenib and lenvatinib are utilized for treating RAI-refractory FTCs ( 8 , 9 ). Numerous guidelines regarding differentiated thyroid carcinoma have been

Open access
Roberto Fiore Division of Endocrinology, Diabetes and Metabolism, University Hospital of Lausanne and University of Lausanne, Hôtel des Patients, Lausanne, Switzerland

Search for other papers by Roberto Fiore in
Google Scholar
PubMed
Close
,
Stefano La Rosa Unit of Pathology, Department of Medicine and Surgery, University of Insubria, Varese, Italy

Search for other papers by Stefano La Rosa in
Google Scholar
PubMed
Close
,
Silvia Uccella Unit of Pathology, Department of Medicine and Surgery, University of Insubria, Varese, Italy

Search for other papers by Silvia Uccella in
Google Scholar
PubMed
Close
,
Deborah Marchiori Unit of Pathology, Department of Medicine and Surgery, University of Insubria, Varese, Italy

Search for other papers by Deborah Marchiori in
Google Scholar
PubMed
Close
, and
Peter A Kopp Division of Endocrinology, Diabetes and Metabolism, University Hospital of Lausanne and University of Lausanne, Hôtel des Patients, Lausanne, Switzerland

Search for other papers by Peter A Kopp in
Google Scholar
PubMed
Close

hypothyroidism was first induced by systemic therapy with checkpoint inhibitors, and then further complicated by consumptive hypothyroidism. In this context, it is worthwhile mentioning that D3 activity can be increased by therapy with tyrosine kinase inhibitors

Open access